India's Cipla announced a $550 million deal last month to buy New York-based InvaGen and a related company in its first foray into manufacturing in the U.S. But a hitch in the deal has developed as New Jersey-based PuraCap Pharmaceutical has filed suit claiming InvaGen breached unspecified obligations to it but "improperly negotiating" with Cipla, the Economic Times reports. Story | More